MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$134,235K
Free Cash flow
-$181,323K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of avai...
Proceeds from issuance of common...
Proceeds from sales of available...
Others
Negative Cash Flow Breakdown
Net (loss) income
Purchases of available-for-sale ...
Repayments of credit facility
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-178,921
-137,570
28,242
16,121
Stock-based compensation
14,872
16,670
19,371
19,087
Depreciation and amortization
6,659
6,368
6,390
6,386
Accretion of available-for-sale securities premiums/discounts
1,607
1,300
1,215
1,244
Non-cash gain on treasury stock received
-
-
-
3,193
Amortization of convertible notes issuance costs
766
657
-
-
Realized gain on investments
17
0
19
0
Non-cash interest expense on liability related to the sale of future royalties
8,683
8,832
7,600
26,036
Non-cash interest expense on credit facility
15,112
14,357
14,905
14,551
Loss on equity method investment
-2,471
-6,719
-
-
Gain on vie's sale of ipr&d assets
0
19,000
-
-
Non-cash transfer of property and equipment to affiliate
24
555
-
-
Accounts receivable
-6,954
-203,185
212,046
47,126
Inventory
-
-
451
-
Prepaid expenses and other current assets
21,527
-4,769
13,182
-12,403
Accounts payable
-3,093
-2,190
15,263
-15,376
Accrued expenses
6,922
-8,635
-13,501
33,541
Deferred revenue
-30,820
-8,599
163,359
-20,580
Operating lease, net
-1,133
-1,212
-1,211
-1,188
Other
2,814
-385
24
34
Net cash (used in) provided by operating activities
-177,469
84,442
13,481
20,491
Purchases of property, plant and equipment
3,854
2,565
2,148
7,489
Purchases of available-for-sale securities
77,137
1,061,577
-
-
Purchases of investments
-
-
136,933
21,642
Proceeds from sales of available-for-sale securities
25,040
23,748
-
-
Proceeds from sales and maturities of investments
-
-
115,339
101,750
Proceeds from maturities of available-for-sale securities
99,634
124,518
-
-
Net cash used in investing activities
43,683
-894,282
-23,742
72,619
Proceeds from the exercises of stock options
2,617
5,048
5,098
507
Proceeds from the sale of future royalties
-
-
-
0
Proceeds from issuance of warrants
0
99,998
0
0
Proceeds from issuance of convertible notes
0
700,000
-
-
Payments of debt issuance costs
0
18,716
0
0
Purchase of capped calls
0
47,880
-
-
Proceeds from issuance of common stock-At The Market Agreement
27,953
48,156
-
-
Payments of issuance costs of common stock-At The Market Agreement
714
1,324
-
-
Proceeds from the issuance of common stock, net of issuance costs paid
-
-
46,832
0
Proceeds from issuance of common stock-Underwriting Public Offering
0
130,000
-
-
Proceeds from credit facility
-
-
-
0
Payments of issuance costs of common stock-Underwriting Public Offering
0
13,393
-
-
Repayments of credit facility
33,385
17,826
66,680
201,625
Proceeds from visirna credit agreement
0
-
-
3,162
Dividends paid by variable interest entity to noncontrolling shareholders
-3,080
41,514
-
-
Net cash provided by financing activities
-449
795,717
-14,750
3,669
Net (decrease) increase in cash, cash equivalents and restricted cash
-134,235
-14,123
-25,011
96,779
Effect of exchange rate changes on cash
-
-
106
-401
Beginning of period
201,643
201,643
226,548
102,685
End of period
54,759
188,517
201,643
226,548
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of...
$99,634K
Proceeds from sales of
available-for-sale securities
$25,040K
Net cash used in
investing activities
$43,683K
(121.63%↑ Y/Y)
Canceled cashflow
$80,991K
Net (decrease)
increase in cash, cash...
-$134,235K
(-588.39%↓ Y/Y)
Canceled cashflow
$43,683K
Non-cash interest
expense on credit...
$15,112K
(-69.02%↓ Y/Y)
Stock-based compensation
$14,872K
(-66.41%↓ Y/Y)
Non-cash interest
expense on liability...
$8,683K
(-54.04%↓ Y/Y)
Accounts receivable
-$6,954K
(-170.66%↓ Y/Y)
Accrued expenses
$6,922K
(-13.00%↓ Y/Y)
Depreciation and
amortization
$6,659K
(-62.04%↓ Y/Y)
Loss on equity method
investment
-$2,471K
Amortization of convertible
notes issuance costs
$766K
Non-cash transfer of
property and equipment to...
$24K
Proceeds from issuance of
common stock-At The...
$27,953K
Dividends paid by variable
interest entity to...
-$3,080K
Proceeds from the
exercises of stock options
$2,617K
(-24.71%↓ Y/Y)
Purchases of
available-for-sale securities
$77,137K
Purchases of property,
plant and equipment
$3,854K
(-74.61%↓ Y/Y)
Net cash (used in)
provided by operating...
-$177,469K
(-211.57%↓ Y/Y)
Canceled cashflow
$62,463K
Net cash provided by
financing activities
-$449K
(-100.64%↓ Y/Y)
Canceled cashflow
$33,650K
Net (loss) income
-$178,921K
(-1378.65%↓ Y/Y)
Deferred revenue
-$30,820K
(-234.12%↓ Y/Y)
Prepaid expenses and
other current assets
$21,527K
(-3.65%↓ Y/Y)
Accounts payable
-$3,093K
(-114.28%↓ Y/Y)
Other
$2,814K
(189.96%↑ Y/Y)
Accretion of
available-for-sale securities...
$1,607K
(-64.64%↓ Y/Y)
Operating lease, net
-$1,133K
(66.84%↑ Y/Y)
Realized gain on
investments
$17K
Repayments of credit
facility
$33,385K
(-83.44%↓ Y/Y)
Payments of issuance
costs of common...
$714K
Buy us a coffee
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)